+44 (0) 1223 755950
+1 832 327 7413
Click on the image to see the image legend
Target | Transforming Growth Factor Beta Receptor II (TGFbR2) |
Origin | Human |
Expression | Recombinant |
Tested Applications | WB, SDS-PAGE |
Host | E. coli |
Conjugation | Unconjugated |
Form | Lyophilized |
Purity | > 95% |
Reconstitution | To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in 10 mM PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in 10 mM PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex. |
Storage | Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles. |
UniProt Primary AC | P37173 (UniProt, ExPASy) |
UniProt Secondary AC | B4DTV5, Q15580, Q6DKT6, Q99474 |
UniProt Entry Name | TGFR2_HUMAN |
Gene Symbol | TGFBR2 |
GeneID | 7048 |
KEGG | hsa:7048 |
String | 9606.ENSP00000351905 |
Molecular Weight | Calculated MW: 20.0 kDa Observed MW (SDS-PAGE): 22 kDa |
Sequence Fragment | Thr23-Gln166 |
Sequence | TIPPHVQK SVNNDMIVTD NNGAVKFPQL CKFCDVRFST CDNQKSCMSN CSITSICEKP QEVCVAVWRK NDENITLETV CHDPKLPYHD FILEDAASPK CIMKEKKKPG ETFFMCSCSS DECNDNIIFS EEYNTSNPDL LLVIFQ |
Tag | N-terminal His tag |
Buffer | Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 5% Trehalose. |
Activity | Active |
Biological Activity | Transforming growth factor beta receptor 2 (TGFBR2) is a tumor suppressor gene that plays a role in the differentiation of striated cells and remodeling of coronary arteries. Single nucleotide polymorphisms (SNPs) of this gene are associated with Marfan syndrome and sudden death in patients with coronary artery disease. Cardiovascular remodeling and T cell activation of TGFBR2 gene suggest that the TGFBR2 gene SNPs are related to the pathogenesis of Kawasaki disease (KD) and coronary artery lesion (CAL). Endoglin can regulate endothelial cell shape changes in response to blood flow, which drive vascular remodeling and establishment of normal vascular morphology during angiogenesis. A functional ELISA assay was conducted to detect the interaction of recombinant human TGFBR2 and recombinant rat Endoglin (ENG). Briefly, TGFBR2 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to ENG-coated microplate wells and incubated for 1 h at 37°C. Wells were washed with PBST and incubated for 1 h with anti-TGFBR2 polyclonal antibody, then aspirated and washed 3 times. After incubation with HRP-conjugated secondary antibody for 1 h at 37°C, wells were aspirated and washed 5 times. TMB substrate solution was added and wells were incubated for 15-25 minutes at 37 °C. Finally, 50 μl stop solution was added to the wells and the absorbance was read at 450/630 nm immediately. The binding activity of recombinant human TGFBR2 and recombinant rat ENG is shown in Figure 2. The EC50 is 36.1 ng/ml. |
Endotoxin Level | < 1.0 EU/µg protein (LAL method) |
Concentration | Prior to lyophilization: 200 µg/ml |
Availability | Shipped within 5-12 working days. |
Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |